NCT04009967View on ClinicalTrials.gov

Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

September 1, 2024

Study Completion Date

March 30, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg every three weeks for 3 cycles only

Trial Locations (1)

Unknown

CHU de Québec-Université Laval, Québec

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

CHU de Quebec-Universite Laval

OTHER

NCT04009967 - Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning | Biotech Hunter | Biotech Hunter